PetMed Express, Inc. (PETS)
| Market Cap | 36.80M -54.9% |
| Revenue (ttm) | 179.02M -21.1% |
| Net Income | -57.29M |
| EPS | -2.74 |
| Shares Out | 21.03M |
| PE Ratio | n/a |
| Forward PE | 25.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,990 |
| Open | 1.800 |
| Previous Close | 1.800 |
| Day's Range | 1.750 - 1.800 |
| 52-Week Range | 1.570 - 4.100 |
| Beta | 0.77 |
| Analysts | Strong Sell |
| Price Target | 2.15 (+22.86%) |
| Earnings Date | Jun 2, 2026 |
About PETS
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthri... [Read more]
Financial Performance
In fiscal year 2026, PetMed Express's revenue was $179.02 million, a decrease of -21.13% compared to the previous year's $226.97 million. Losses were -$57.29 million, 813.5% more than in 2025.
Financial StatementsAnalyst Summary
According to one analyst, the rating for PETS stock is "Strong Sell" and the 12-month stock price target is $2.15.
News
PetMed Express to continue as public company after receipt of buyout offers
The company stated in its Q4 earnings announcement: “In December 2025, the Company received two unsolicited, non-binding preliminary proposals from two separate third parties to acquire all of the out...
PetMed Express reports Q4 EPS (19c) vs. (56c) last year
Reports Q4 revenue $42.82M vs. $50.76M last year. “We are pleased to report a modest sequential quarterly increase in fourth quarter net sales, demonstrating positive momentum as we close out…
PetMed Express Earnings Call Transcript: Q4 2026
Fiscal 2026 saw a 21.1% revenue decline and a $57.3M net loss, but operational improvements, cost reductions, and technology upgrades led to sequential Q4 sales growth and improved gross margin. The board rejected acquisition offers, focusing on long-term independence.
PetMed Express Earnings release: Q4 2026
PetMed Express released its Q4 2026 earnings on June 2, 2026, summarizing the period's financial results.
PetMed Express Annual report: Q4 2026
PetMed Express has published its Q4 2026 annual report on June 2, 2026.
PetMeds® Announces Fourth Quarter and Fiscal Year 2026 Financial Results
DELRAY BEACH, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its fourth quarter and f...
PetMed Express, Inc. to Report Fourth Quarter and Fiscal Year 2026 Financial Results on Tuesday, June 2, 2026
DELRAY BEACH, Fla., May 29, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the fourth q...
PetMed Express partners with Rural King on pet pharmacy offering
PetMed Express (PETS) announced a strategic partnership with Rural King to launch a new pet pharmacy offering, expanding access to prescription medications, preventatives and pet health products for c...
PetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channels
Collaboration expands access to affordable pet medications for rural communities nationwide Collaboration expands access to affordable pet medications for rural communities nationwide
PetMed Express, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PetMed Express , Inc. , (“ PetMed " or the "Company") ( NASDAQ : PETS) investors that the firm has initiated an investigat...
PetMed Express Quarterly report: Q3 2026
PetMed Express has published its Q3 2026 quarterly earnings report on February 4, 2026.
PetMed Express Quarterly report: Q2 2026
PetMed Express has published its Q2 2026 quarterly earnings report on December 19, 2025.
PetMed Express Quarterly report: Q1 2026
PetMed Express has published its Q1 2026 quarterly earnings report on December 19, 2025.
Cardone Ventures announces $4.25 per share proposal to acquire PetMed Express
Cardone Ventures submitted an unsolicited, non-binding proposal to acquire PetMed Express (PETS) for $4.25 per share in cash, representing an implied equity value of approximately $89M. The proposal w...
Cardone Ventures Announces Unsolicited $4.25 Per Share All-Cash Proposal to Acquire PetMed Express
MIAMI--(BUSINESS WIRE)--Cardone Ventures, backed by billionaire investor, Grant Cardone and his business partners Brandon and Natalie Dawson, today announced that it has submitted an unsolicited, non-...
Why Did Penny Stock PetMed Express (PETS) Soar over 68%?
Shares in PetMed Express ($PETS), an American online pet pharmacy, closed Thursday’s trading 68.36% higher following an $84 million acquisition offer from SilverCape Investments. The Singapore-based i...
PetMed Express to ‘carefully review’ SilverCape’s acquisition proposal
PetMed Express (PETS) received an unsolicited and non-binding acquisition proposal from SilverCape Investments to acquire all of the outstanding shares of the Company for $4 per share in cash, subject...
PetMed Express Comments on Unsolicited and Non-Binding Acquisition Proposal Received From SilverCape Investments Limited
DELRAY BEACH, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company” or “PetMeds”), today confirmed that it has rece...
PetMed Express announces Holiday Collection
PetMed Express (PETS), d/b/a PetMeds and parent company of PetCareRx, unveiled its new Holiday Collection. “With more pet parents treating their furry friends like true members of the family, holiday…
PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them
DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today unveiled its new Holiday Collection, a ...
PetMed Express Proxy statement: Proxy Filing
PetMed Express filed a proxy statement on December 10, 2025, providing details for shareholder voting and corporate governance matters.
PetMeds Extends Existing Shareholder Rights Plan
DELRAY BEACH, Fla., Nov. 26, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today announced that its Board of Directors (...
Pets At Home's Shares Purr As Retailer Avoids Fresh Profit Warning
Despite news of further weak trading, Pets at Home's share price spiked on Wednesday as the retailer averted another confidence-crushing profit warning.
PetMed Express reports preliminary Q2 revenue $43.4M-$44.5M
For the fiscal second quarter ended September 30, 2025, net sales are estimated to range from $43.4 million to $44.5 million compared to $58.0 million in the prior year period.
PetMed Express, Inc. Announces Preliminary Second Quarter Results and Filing of Form 12b-25; Company Receives Expected Notice of Non-Compliance from Nasdaq
DELRAY BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today announced preliminary second quarter fis...